A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Summary

BTK participates in a variety of signal transduction of innate and adaptive immunity, and has an important role in cell proliferation, differentiation and apoptosis. The impact of BTK inhibitors on hematological malignancies and autoimmune diseases has been well studied. This project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of the selective BTK inhibitor Orelabrutinib in the management of refractory ITP.

Timeline

Start

2021-09-01

Primary completion

2023-12-31

Completion

2024-06-01

Drugs

Indications